EZH2 Monoclonal Antibody (AC22), eBioscience™, Invitrogen™

Description

• Description: The monoclonal antibody AC22 recognizes EZH2 (Enhancer of zeste homolog 2), a member of the polycomb group (PcG) proteins responsible for repression of gene expression through recognition and modification of histone methylation and chromatin structure
• EZH2 comprises the catalytic subunit of the polycomb repressive complex 2 (PRC2) and directly represses gene expression through methylation of histone H3 on lysine 27 (H3K27) as well as direct protein targets such as GATA4
• The PRC2 complex gene repression is necessary for proper development and differentiation
• Underexpression of EZH2 is linked to abnormal developmental patterning and a loss of stem cell pluripotency, while overexpression of EZH2 is present in many tumors and correlates with poor prognosis in melanoma, breast, and prostate cancer
• Applications Reported: This AC22 antibody has been reported for use in immunoprecipitation, western blotting, and immunocytochemistry
• Applications Tested: This AC22 antibody has been tested by immunocytochemistry of methanol-fixed cells and can be used at less than or equal to 5 μg/mL
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Purity: Greater than 90%, as determined by SDS-PAGE
• Aggregation: Less than 10%, as determined by HPLC
• Filtration: 0.2 μm post-manufacturing filtered
• EZH2 (Histone-lysine N-methyltransferase) is a member of the Polycomb-group (PcG) family
• PcG family members form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations
• This protein associates with the embryonic ectoderm development protein, the VAV1 oncoprotein, and the X-linked nuclear protein
• EZH2 may play a role in the hematopoietic and central nervous systems
• Mutations affecting EZH2 can cause Weaver syndrome (WVS).